Skip to main content
OpenTrials

Clinical trial condition

Hepatitis C, Chronic

Explore clinical trials studying Hepatitis C, Chronic. Study availability and eligibility vary by location and protocol.

314 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Hepatitis C, Chronic trial results

Completed

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

NCT01353248

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Birmingham Gastroenterology Associates, P.C. Birmingham, Alabama, United States
  • Digestive Health Specialists of the Southeast Dothan, Alabama, United States
  • Advanced Clinical Research Institute Anaheim, California, United States
  • Southern California Liver Centers Coronado, California, United States
View all 43 locations
View Trial Details
Completed

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

NCT01435226

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • University of Arizona Tucson, Arizona, United States
  • Advanced Clinical Research Institute, LLC Anaheim, California, United States
  • California Liver Institute Beverly Hills, California, United States
  • SCTI Research Foundation Liver Center Coronado, California, United States
View all 51 locations
View Trial Details
Completed

A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

NCT00115908

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • Concord Repatriation General Hospital Concord, New South Wales, Australia
  • John Hunter Hospital New Lambton Heights, New South Wales, Australia
  • Westmead Hospital Westmead, New South Wales, Australia
View all 87 locations
View Trial Details
Completed

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +15 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Anaheim, California, United States
  • GSK Investigational Site Arcadia, California, United States
View all 227 locations
View Trial Details
Completed

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

NCT00516321

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +15 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site La Jolla, California, United States
View all 191 locations
View Trial Details
Completed

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

NCT00800735

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Sacramento, California, United States
  • San Francisco, California, United States
  • Lutherville, Maryland, United States
  • Manhasset, New York, United States
View all 23 locations
View Trial Details
Completed

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

NCT01853254

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Birmingham, Alabama, United States
  • La Jolla, California, United States
  • Long Beach, California, United States
  • San Diego, California, United States
View all 67 locations
View Trial Details
Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

NCT00623428

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Birmingham, Alabama, United States
  • La Jolla, California, United States
  • Lancaster, California, United States
  • Long Beach, California, United States
View all 101 locations
View Trial Details

Related conditions